Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases

Juliette Viala, Daniel Vanel, Philippe Meingan, Eric Lartigau, Patrice Carde, Markus Renschler

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

PURPOSE: To evaluate magnetic resonance (MR) imaging results after administration of gadolinium texaphyrin, a tumor-selective radiation sensitizer that is detectable at MR imaging, and to determine an appropriate intravenous dose of gadolinium texaphyrin for repeated injections during radiation therapy, the dose-limiting toxicity of reiterated doses of gadolinium texaphyrin, the maximal tolerated dose, the biolocalization of gadolinium texaphyrin (as assessed at MR examinations), and the response to treatment. MATERIALS AND METHODS: Ten daily intravenous injections of gadolinium texaphyrin, each followed by whole-brain radiation therapy (total of 10 fractions, 30 Gy), were administered to patients with brain metastases in a multicenter study. At the study institution, 11 patients underwent MR imaging before and after the first injection, after the 10th injection, and 8 weeks after entry into the study. RESULTS: MR imaging revealed selective drug uptake in metastases, without enhancement of normal brain tissue. In 10 patients, tumor uptake was higher after the 10th injection than after the first injection, which indicated accumulation of gadolinium texaphyrin in metastases. One lesion was visible only after the 10th injection and not at the pretherapeutic MR examination with injection of conventional gadolinium- based contrast material. Response to treatment was defined as a reduction in the size of the metastases between the preinjection MR study and the last MR study; seen patients achieved partial remission with tumor regression exceeding 50% of the initial size, and four achieved a minor response with less than 50% tumor regression. CONCLUSION: These preliminary results indicate that gadolinium texaphyrin is tumor selective and that brain metastases can be depicted at MR imaging long after the administration of gadolinium texaphyrin.

Original languageEnglish
Pages (from-to)755-759
Number of pages5
JournalRadiology
Volume212
Issue number3
Publication statusPublished - Sep 1999

Fingerprint

Radiation-Sensitizing Agents
Magnetic Resonance Imaging
Neoplasm Metastasis
Brain
Injections
Magnetic Resonance Spectroscopy
Neoplasms
Radiotherapy
Maximum Tolerated Dose
motexafin gadolinium
Gadolinium
Brain Neoplasms
Intravenous Injections
Contrast Media
Multicenter Studies

Keywords

  • Brain neoplasms, MR
  • Brain neoplasms, secondary
  • Brain neoplasms, therapeutic radiology
  • Contrast media
  • Texaphyrins

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Viala, J., Vanel, D., Meingan, P., Lartigau, E., Carde, P., & Renschler, M. (1999). Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases. Radiology, 212(3), 755-759.

Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging : Preliminary results in brain metastases. / Viala, Juliette; Vanel, Daniel; Meingan, Philippe; Lartigau, Eric; Carde, Patrice; Renschler, Markus.

In: Radiology, Vol. 212, No. 3, 09.1999, p. 755-759.

Research output: Contribution to journalArticle

Viala, J, Vanel, D, Meingan, P, Lartigau, E, Carde, P & Renschler, M 1999, 'Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases', Radiology, vol. 212, no. 3, pp. 755-759.
Viala, Juliette ; Vanel, Daniel ; Meingan, Philippe ; Lartigau, Eric ; Carde, Patrice ; Renschler, Markus. / Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging : Preliminary results in brain metastases. In: Radiology. 1999 ; Vol. 212, No. 3. pp. 755-759.
@article{def531caf8c045f5bc66189121fd2cfe,
title = "Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases",
abstract = "PURPOSE: To evaluate magnetic resonance (MR) imaging results after administration of gadolinium texaphyrin, a tumor-selective radiation sensitizer that is detectable at MR imaging, and to determine an appropriate intravenous dose of gadolinium texaphyrin for repeated injections during radiation therapy, the dose-limiting toxicity of reiterated doses of gadolinium texaphyrin, the maximal tolerated dose, the biolocalization of gadolinium texaphyrin (as assessed at MR examinations), and the response to treatment. MATERIALS AND METHODS: Ten daily intravenous injections of gadolinium texaphyrin, each followed by whole-brain radiation therapy (total of 10 fractions, 30 Gy), were administered to patients with brain metastases in a multicenter study. At the study institution, 11 patients underwent MR imaging before and after the first injection, after the 10th injection, and 8 weeks after entry into the study. RESULTS: MR imaging revealed selective drug uptake in metastases, without enhancement of normal brain tissue. In 10 patients, tumor uptake was higher after the 10th injection than after the first injection, which indicated accumulation of gadolinium texaphyrin in metastases. One lesion was visible only after the 10th injection and not at the pretherapeutic MR examination with injection of conventional gadolinium- based contrast material. Response to treatment was defined as a reduction in the size of the metastases between the preinjection MR study and the last MR study; seen patients achieved partial remission with tumor regression exceeding 50{\%} of the initial size, and four achieved a minor response with less than 50{\%} tumor regression. CONCLUSION: These preliminary results indicate that gadolinium texaphyrin is tumor selective and that brain metastases can be depicted at MR imaging long after the administration of gadolinium texaphyrin.",
keywords = "Brain neoplasms, MR, Brain neoplasms, secondary, Brain neoplasms, therapeutic radiology, Contrast media, Texaphyrins",
author = "Juliette Viala and Daniel Vanel and Philippe Meingan and Eric Lartigau and Patrice Carde and Markus Renschler",
year = "1999",
month = "9",
language = "English",
volume = "212",
pages = "755--759",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "3",

}

TY - JOUR

T1 - Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging

T2 - Preliminary results in brain metastases

AU - Viala, Juliette

AU - Vanel, Daniel

AU - Meingan, Philippe

AU - Lartigau, Eric

AU - Carde, Patrice

AU - Renschler, Markus

PY - 1999/9

Y1 - 1999/9

N2 - PURPOSE: To evaluate magnetic resonance (MR) imaging results after administration of gadolinium texaphyrin, a tumor-selective radiation sensitizer that is detectable at MR imaging, and to determine an appropriate intravenous dose of gadolinium texaphyrin for repeated injections during radiation therapy, the dose-limiting toxicity of reiterated doses of gadolinium texaphyrin, the maximal tolerated dose, the biolocalization of gadolinium texaphyrin (as assessed at MR examinations), and the response to treatment. MATERIALS AND METHODS: Ten daily intravenous injections of gadolinium texaphyrin, each followed by whole-brain radiation therapy (total of 10 fractions, 30 Gy), were administered to patients with brain metastases in a multicenter study. At the study institution, 11 patients underwent MR imaging before and after the first injection, after the 10th injection, and 8 weeks after entry into the study. RESULTS: MR imaging revealed selective drug uptake in metastases, without enhancement of normal brain tissue. In 10 patients, tumor uptake was higher after the 10th injection than after the first injection, which indicated accumulation of gadolinium texaphyrin in metastases. One lesion was visible only after the 10th injection and not at the pretherapeutic MR examination with injection of conventional gadolinium- based contrast material. Response to treatment was defined as a reduction in the size of the metastases between the preinjection MR study and the last MR study; seen patients achieved partial remission with tumor regression exceeding 50% of the initial size, and four achieved a minor response with less than 50% tumor regression. CONCLUSION: These preliminary results indicate that gadolinium texaphyrin is tumor selective and that brain metastases can be depicted at MR imaging long after the administration of gadolinium texaphyrin.

AB - PURPOSE: To evaluate magnetic resonance (MR) imaging results after administration of gadolinium texaphyrin, a tumor-selective radiation sensitizer that is detectable at MR imaging, and to determine an appropriate intravenous dose of gadolinium texaphyrin for repeated injections during radiation therapy, the dose-limiting toxicity of reiterated doses of gadolinium texaphyrin, the maximal tolerated dose, the biolocalization of gadolinium texaphyrin (as assessed at MR examinations), and the response to treatment. MATERIALS AND METHODS: Ten daily intravenous injections of gadolinium texaphyrin, each followed by whole-brain radiation therapy (total of 10 fractions, 30 Gy), were administered to patients with brain metastases in a multicenter study. At the study institution, 11 patients underwent MR imaging before and after the first injection, after the 10th injection, and 8 weeks after entry into the study. RESULTS: MR imaging revealed selective drug uptake in metastases, without enhancement of normal brain tissue. In 10 patients, tumor uptake was higher after the 10th injection than after the first injection, which indicated accumulation of gadolinium texaphyrin in metastases. One lesion was visible only after the 10th injection and not at the pretherapeutic MR examination with injection of conventional gadolinium- based contrast material. Response to treatment was defined as a reduction in the size of the metastases between the preinjection MR study and the last MR study; seen patients achieved partial remission with tumor regression exceeding 50% of the initial size, and four achieved a minor response with less than 50% tumor regression. CONCLUSION: These preliminary results indicate that gadolinium texaphyrin is tumor selective and that brain metastases can be depicted at MR imaging long after the administration of gadolinium texaphyrin.

KW - Brain neoplasms, MR

KW - Brain neoplasms, secondary

KW - Brain neoplasms, therapeutic radiology

KW - Contrast media

KW - Texaphyrins

UR - http://www.scopus.com/inward/record.url?scp=0032874534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032874534&partnerID=8YFLogxK

M3 - Article

C2 - 10478243

AN - SCOPUS:0032874534

VL - 212

SP - 755

EP - 759

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 3

ER -